Philadelphia -- Daniel J. Rader, MD, chief, Division of Translational Medicine and Human Genetics, and Edward Morrisey, PhD, professor of Medicine and Cell and Developmental Biology, Perelman School of Medicine, and Scientific Director at the Penn Institute for Regenerative Medicine,  and researchers at the Medical College of Wisconsin received a five-year, $9 million grant for stem cell research from the National Institutes of Health’s National Human Genome Research (NHGRI) and the National Heart Lung and Blood (NHLBI) Institutes.

The funding will be used in a collaborative study between both institutions on the role of genetics in cardiovascular disease. Rader and Morrisey will take fat cells and change them into induced pluripotent stem cells, or iPS cells, which will be turned into liver cells to learn more about the causes of coronary artery disease and metabolic disorders.

Cardiovascular disease causes more American deaths than any other disease. Genetic studies conducted in 100,000 participants found 95 specific genetic locations showing a link to high lipid levels, which the liver controls. The researchers will study iPS-derived liver cells from 300 patients with particular genetic profiles to find out why some of those with certain genetic mutations produce high levels of plasma lipids.

"These studies will illuminate how specific genes behave in different tissues and should clarify the mechanisms by which a gene associated with a disease affects the biology of different tissues," said Susan B. Shurin, M.D., acting director of the NIH's National Heart, Lung, and Blood Institute.  "Understanding the cellular and tissue biology will allow us to develop and test new therapies and prevention methods.  These approaches using iPS cells on a large scale could improve the predictive value of preclinical testing, benefit regenerative medicine, and reduce the need for animal models of disease."

Stephen, A. Duncan, PhD, professor of cell biology, neurobiology and anatomy, and director of the Medical College of Wisconsin’s Regenerative Medicine and Stem Cell Biology program, is a co-principal investigator.

The NHLBI release is available here:


Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.

Share This Page: